A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and Corporis

Recruiting now · Not applicable

Conditions studied: Tinea Corporis, Tinea Cruris

In brief

This pilot study will test intra-lesional immunotherapy (MMR vaccine) injections as a treatment for recalcitrant tinea cruris and corporis in patients aged 10-60 years who have not improved with standard antifungal treatments. \*Eligibility: Participants must have recalcitrant tinea, defined as: * Rapid progression or large areas of skin affected, * Infection in multiple family members, especially females and children * Rapid relapse after prior treatment * Suspected resistant T. indotineae (based on travel history or contact with affected individuals from high-prevalence regions) * Failure of at least 2 courses of systemic antifungal therapy in the past 3 months Treatment: Patients will receive intra-lesional MMR vaccine injections into the active borders of affected lesions every 2 weeks for up to 6 weeks. If partial improvement occurs but complete clearance is not achieved, the course may be repeated for another 6 weeks. Pulse itraconazole will be given during the first 2 weeks. Monitoring: At each study visit, clinicians will assess the extent of affected skin and monitor symptoms particularly itching. Safety will be closely observed, including injection-site reactions, fever, initial flare of lesions, and any rare serious allergic reactions. Goal: To evaluate the safety and effectiveness of intra-lesional MMR immunotherapy for patients with tinea that has been difficult to treat.

Key facts

Study ID

NCT07312604

Run by

Abeer Mohamed Abdelaziz Elkholy

People needed

50

Starts

2025-12-09

Expected to finish

2026-03-09

Last updated by the study team

2025-12-31

Who can join

Age: 10 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between 10 - 60 years.
• Evidence of recalcitrant tinea e.g. (rapid progression \& large areas affected of the body, affection of more than one family members especially females \& children, rapid relapse after treatment, suspicion of resistant T. indotineae strain by history of traveling abroad \& contact with Indians or contact with a case coming from travel \& with contact to Indians.
• Patients failed at least 2 courses of systemic antifungal therapy in the last 3 months.
• Safe contraception during the study (for females in the childbearing period).

You may not qualify if…

• Pregnant or lactating women, as well as women of childbearing potential not using an effective method of contraception.
• Age <10 years or > 60 years.
• Immunocompromised patients e.g. (uncontrolled DM or HIV patients).
• Naïve patients without previous systemic antifungal treatment.
• Unreliable patients.

Where it is running

• Mansoura University Hospital — Al Mansurah, Dakahlia Governorate, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.